Biogen Idec, Inc. (BIIB) Tops Q3 Adj-EPS by 8c
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Revenue Growth %: +4.3%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +4.3%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q3 EPS of $1.61, ex-items, $0.08 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.27 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- Children's Place (PLCE) Misses Q2 EPS by 20c
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
